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a b s t r a c t
A(H3N2) inﬂuenza viruses have circulated in humans since 1968, and antigenic drift of the hemagglu-
tinin (HA) protein continues to be a driving force that allows the virus to escape the human immune
response. Since the major antigenic sites of the HA overlap into the receptor binding site (RBS) of the
molecule, the virus constantly struggles to effectively adapt to host immune responses, without
compromising its functionality. Here, we have structurally assessed the evolution of the A(H3N2) virus
HA RBS, using an established recombinant expression system. Glycan binding speciﬁcities of nineteen A
(H3N2) inﬂuenza virus HAs, each a component of the seasonal inﬂuenza vaccine between 1968 and 2012,
were analyzed. Results suggest that while its receptor-binding site has evolved from one that can bind a
broad range of human receptor analogs to one with a more restricted binding proﬁle for longer glycans,
the virus continues to circulate and transmit efﬁciently among humans.
Published by Elsevier Inc.
Introduction
Inﬂuenza A viruses are classiﬁed into subtypes according to the
serological reactivity of their surface glycoproteins, hemagglutinin
(HA) and neuraminidase (NA) (World Health Organization, 1980).
Currently, 18 HA (H1–H18) and 11 NA (N1–N11) variants have been
identiﬁed in aquatic birds and bats (Fouchier et al., 2005; Tong et al.,
2012, 2013), and, of the 198 theoretical HA/NA combinations, only
three inﬂuenza A subtypes in the last 100 years have successfully
adapted to the human population to cause four pandemics, H1N1 in
1918 and 2009, H2N2 in 1957, and H3N2 in 1968 (Bean et al., 1992;
Garten et al., 2009; Reid and Taubenberger, 2003; Scholtissek et al.,
1978). This limited number suggests a virus must undergo a number
of changes in its genes in order to successfully adapt to humans
(Herfst et al., 2012; Imai et al., 2012). Several factors contribute to
virus adaptation to humans and one is the ability of the HA virus coat
protein to bind to sialic acid containing receptors on the host cell
(Imai and Kawaoka, 2012). It is the nature of the sialic acid linkage
preference of a virus, which varies in different host species, that helps
maintain the species barrier and contributes to efﬁcient infection and
transmission between humans (Matrosovich et al., 2004; Nicholls et
al., 2007; Rogers et al., 1983; Shinya et al., 2006; van Riel et al., 2006,
2007; Varki, 2007; Varki and Varki, 2007).
In humans, inﬂuenza A viruses utilize glycoproteins with complex
carbohydrates containing terminal α2-6-linked sialic acids on the cell
surface of upper respiratory tract epithelial cells in order to attach and
initiate an infection (Baum and Paulson, 1990; Couceiro et al., 1993).
Conversely, most aquatic bird viruses bind to α2-3-linked sialic acid
containing receptors in the avian intestinal tract. Previous studies
identiﬁed a number of key receptor binding site (RBS) mutations,
responsible for switching avian/human receptor speciﬁcity in H1, H2
and H3 subtypes. In H1 subtypes, a Glu190Asp and Gly225Asp double
mutation renders the HA capable of binding human α2-6 receptors
(Matrosovich et al., 2000; Stevens et al., 2006a). For H2 and H3, two
different mutations, Gln226Leu and Gly228Ser correlate with a shift to
human receptor speciﬁcity (Connor et al., 1994; Rogers et al., 1983). As
yet, the nature of the switch from other avian pandemic potential
subtypes, such as H5 (Herfst et al., 2012; Imai et al., 2012), H7 (Gao
et al., 2013), and H9 (Wan et al., 2008) necessary to cross the species
barrier into the human population is unknown, although the recent
H7N9 outbreak in China suggests this virus may prefer the H2/H3
route (Gao et al., 2013).
As seen with H1N1, H2N2 and H3N2 inﬂuenza A viruses, once
established in the human population, the virus coat proteins hemag-
glutinin (HA) and to a lesser extent neuraminidase (NA) undergo
continual change to evade the human immune system. This antigenic
drift, as highlighted by the H3N2 inﬂuenza A virus (Pereira and Schild,
1971), can continue for many decades, whereby the human immune
system targets speciﬁc antigenic sites (Daniels et al., 1983; Popova
et al., 2012; Stray and Pittman, 2012; Webster and Laver, 1980; Wiley
et al., 1981) in and around the virus RBS. The virus attempts to evade
these responses by introducing escape mutations that successfully
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reduce host immune recognition, without compromising other func-
tions, such as receptor binding. Due to the close proximity of the RBS
and antigenic sites, the interplay between antigenic drift and potential
changes in receptor binding is an important factor which has been
studied by a number of groups for both H1N1 (Aytay and Schulze,
1991; Das et al., 2011; Hensley et al., 2009) and H3N2 viruses (Daniels
et al., 1987; Lin et al., 2012; Underwood et al., 1987). Here, we have
assessed structural changes in the HA, including changes in the rece-
ptor binding preferences of a number of H3 recombinant HA (recHA)
proteins. Results suggest that its RBS has evolved from one that can
bind a broad range of human receptor analogs to one with a more
restricted binding to longer glycans alone.
Results
Sequence and structural evolution of the H3 HA ectodomain
Comparison of the 2013 HA0 ectodomain consensus sequencewith
one from 1968 reveals that it still shares 87% identity to the 1968 virus
HA (Fig. 1A). With the HA2 component of the HA being 95% identical,
the majority of the differences are therefore in the HA1 globular head
region (81% identity). Structurally, the majority of these HA1 differ-
ences also belong to surface residues of the HA1 domainwith only 70%
identity (Fig. 1A). Similarly, examination of residues in the A(H3N2)
virus HA that have been subject to positive selection since 1968 also
shows that the majority involved residues on the surface of the
globular head of the HA (Fig. 1A) (Bush et al., 1999a, 1999b; Smith
et al., 2004; Tusche et al., 2012; Wiley and Skehel, 1987), with many
surrounding the receptor binding site (RBS) (Fig. 1B).
To assess the structural consequences of evolutionary changes
among these A(H3N2) virus HAs, we crystallized the full length
recombinant HA (recHA) ectodomain proteins from HK68, PtChal-
mers73 and Victoria11, as well as the HA1 domains of Perth09 and
Christchurch11. Upon removal of the foldon trimerization domain, all
full-length recHAs puriﬁed and crystallized as trimers while the HA1
domain proteins were monomeric. Diffraction datasets were collected
from native protein crystals of each HA, as described in the methods
and Table 2. All crystal structures were determined by the molecular
replacement method, using the previously published HK68 HA
(PDB:2HMG) as a searchmodel (Weis et al., 1990). Amino acid residues
in each structure are numbered consecutively, according to the ectod-
omain fragments of the mature HA1 and HA2 subunits, respectively.
The full length PtChalmers73 H3 HA exhibited a high degree of
amino acid sequence identity to HK68 (97% across the entire HA),
while Victoria11 was more distant (86%) (Table 3). Despite these
sequence differences, the overall structures of PtChalmers73 and
Victoria11 HAs are similar to that of HK68. Each HA is a trimer of
identical monomeric subunits, each composed of a virus membrane-
proximal α-helix-rich stem and a membrane-distal globular head.
Comparison of the HA1/HA2 monomer of each structure with that of
the HK68 virus HA as well as to two previously published HAs from
A/Norway/807/2004 (Norway04) and A/Malaysia/33386/2005 (Malay-
sia05) revealed structurally similar molecules despite their 43 year
separation (Lin et al., 2012). All Cα atoms in the HA1/HA2 monomers
of PtChalmers73, Norway04, Malaysia05 and Victoria11 superimposed
onto HK68 to give root mean square deviations (RMSD) of only 0.39 Å,
0.76 Å, 0.73 Å and 0.68 Å, respectively (Table 4). Similarly when only
the HA1 domains are compared to HK68, including the HA1 only
models for Perth09 and Christchurch11, RMSD values range between
0.27 Å and 0.8 Å (Table 5), indicating a high degree of structural
homology in the conﬁguration of these HAs, despite 43 years between
the earliest and most recent HA.
HA glycosylation
Since the A(H3N2) virus ﬁrst adapted to humans in 1968, the
virus HA has evolved from a protein with 7 potential glycosylation
Fig. 1. (A) To analyze HA evolution with time the HA sequences for A(H3N2) viruses were grouped according to year and consensus sequences were generated. Datasets
corresponding to the HA0, HA1, HA2, as well as only surface residues (HA1-srf and HA2-srf) were also generated for comparison. Data was plotted as percentage change in
identity to the 1968 consensus. Years where the H3 component of the Northern hemisphere vaccine was changed are marked with brown squares. (B) Surface representation
of the Victoria11 HA monomer highlighting carbohydrate sites (CHO; blue) as well as surface residues (orange) that have undergone substitution and that were maintained in
subsequent years. All structural ﬁgures were generated with MacPyMol (Delano, 2002).
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Fig. 2. (A) Structural overlap of A(H3N2) HA monomers. HA monomers, HK68 (gray), PtChalmers73 (green) and Victoria11 (orange) are shown as tubes and the locations of
glycosylation sites are highlighted with Asn side chain as red spheres. These sites if present on speciﬁc HAs are marked with squares colored according to the same HA coloring.
(B) RBS overlap of HK68 (gray), PtChalmers73 (green), Perth09 (magenta), Christchurch11 (cyan) and Victoria11 (orange). Previously published H3 HAs, Norway04 (blue) and
Malaysia05 (yellow) (Lin et al., 2012) were also used in the alignment. (C) SDS-PAGE of various recombinant H3 HA proteins indicates an increase in MWas the predicted number of
glycosylation sites increase with time.
98 131 140 144 146 153 159  183 196  219 228 
|  |     |  | |    |  |  |   | |        |
1968 Y TQNGGSNA-K GSG WLTKSGS H-PSTNQEQTSLYV SRPWVRGLSS
1969 . ........-K    ... ....... .-............ ..........
1970 . ........-K    ... ....... .-............ ..........
1971 . ........-K    ... ....... .-............ ..........
1972 . ........-K    D.. ..Y.... .-...D........ ..........
1973 . ........-K    D.. ..Y.... .-...D........ ..........
1974 . ........-K    D.. ..Y.... .-...D....N... ..........
1975 . ........-K    DN. ..Y.... .-...D....N... ..........
1976 . ......S.-K    DN. ..Y.... .-...DK...D... ..........
1977 . ......Y.-K    DN. ..Y..E. .-...DK...N... ..........
1978 . ......Y.-K    DNS ..Y..E. .-...DK...N... ..........
1979 . ..S...Y.-K    DNS ..YE.E. .-...DK...N... ..........
1980 . ..S...Y.-K    DNS ..YE.E. .-...DK...N... ..........
1981 . ..S...Y.-K    DNS ..YE.E. .-...DK...N... ..........
1982 . ..S...Y.-K    DNS ..YE.E. .-...DK...N... ..........
1983 . ..S...Y.-K    VNS ..YE.E. .-...DK...N... ..........
1984 . ..S...Y.-K    VNS ..YE.E. .-...DK...N... ..........
1985 . ..S...Y.-K    VNS ..YE.E. .-...DK...N... ..........
1986 . ..S...Y.-K    VNS ..YE.EY .-...DK...N... ..........
1987 . ..S...Y.-K    VNS ..HE.EY .-...DR...N... ..........
1988 . ..S...Y.-K    VNS ..HE.EY .-...DR...N... ..........
1989 . A.S...Y.-K    VNS ..HE.EY .-...DR...N... ..........
1990 . A.S...Y.-K    VNS ..HE.EY .-...DR...N... ..........
1991 . A.S.E.Y.-K    VKS ..HE.DY .-...DR....... ..........
1992 . A.S.E.Y.-K    VKS ..HE.EY .-...DR....... ..........
1993 . A.D.K.Y.-K    VNS ..H.LEY .-...DSD...... ..........
1994 . A.D.K.Y.-K    VNS ..H.LEY .-...DSD...... F.........
1995 . A.D.K.Y.-K    VNS ..H.LEY .-...DSD...... .......I..
1996 . A.D.T.Y.-K    VKS ..H.LEY .-...DSD...... .......V..
1997 . A...T.Y.-K    VKS ..H.LEY .-...DSD...... .......V..
1998 . A...T.Y.-K    IKS ..HQLKY .-...DSD.....A .......V..
1999 . A...T.S.-K    IKS ..HQLKY .-...DSD.I...A .......V..
2000 . A...T.S.-K    IKS ..HQLKY .-...DSD.I...A .......V..
2001 . A...T.S.-K    NKS ..HQLKY .-...DSD.I...A .......V..
2002 . A...T.S.-K    DKS ..HQLKY .-.G.DSD.I...A .......V..
2003 . ....T.S.-K    NKS ...HLKY .-.G.DSD.I...A ...R..DV..
2004 . ....T.S.-K    NNS ...HLKF .-.G.DND.I...A ...R..DIP.
2005 . ....T.S.-K    NNS ...HLKF .-.G.DND.I...A ...R..DIP.
2006 . ....T.S.-K    NNS ...HLKF .-.G.DND.IF..A ...R..NIP.
2007 . ....T.S.-I    NNS ...HLKF .-.G.DND.IF..A ...R..NIP.
2008 . ....T.S.-I    NNS ...HLKF .-.G.DND.IF..A ...R..NIP.
2009 . ....T.S.-I    NNS ...HLNF .-.G.DKD.IF..A ...R..NIP.
2010 . ....T.S.-I    NNS ...HLNF .-.G.DKD.IF..A ...R..NIP.
2011 . ....T.S.-I    NNS ...HLNF .-.G.DKD.IF..A ...R..NIP.
2012 . ....T.S.-I    NNS ...HLNF .-.G.DKD.IF..A ...RI.NIP.
2013 . ....T.S.-I    N.S ...HLNF .-.G.DKD.IF..A ...RI.NIP.
Fig. 3. Consensus sequence alignment of the A(H3N2) virus RBS by year. RBS residues that overlap onto recognized antigenic sites (AS) (Daniels et al., 1983; Popova et al.,
2012; Stray and Pittman, 2012; Wiley et al., 1981) are colored red for AS-A, yellow for AS-B, and blue for AS-D.
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sites to one with 12–13 potential sites (Fig. 2A), six of which
(Asn122, Asn126, Asn133, Asn144, Asn165 and Asn246) are within
or near to both the RBS and known antigenic sites (Fig. 2B). All HAs
were expressed in an insect expression system and thus should
possess N-carbohydrates at these sites. However, occupied glyco-
sylation sites are often difﬁcult to resolve structurally due to carb-
ohydrate ﬂexibility in the crystals. In the models reported here, N-
carbohydrates were clearly visible within the electron density at
six of the seven potential sites in HK68 (HA1: Asn22, Asn38,
Asn81, Asn165, Asn285 and HA2: Asn154; mature H3 HA number-
ing), at ﬁve of eight potential sites within PtChalmers73 (HA1:
Asn38, Asn63, Asn81, Asn165 and Asn285) and only eight of
potential thirteen glycosylation sites in Victoria11 (HA1: Asn22,
Asn38, Asn63, Asn133, Asn165, Asn246, Asn285 and HA2:
Asn154). SDS-PAGE also suggests occupancy of additional
potential sites during the virus’ 46 year circulation in humans
(Fig. 2C).
Evolution of the receptor binding site (RBS)
The RBS at the membrane distal end of each HA monomer
(Fig. 2A), comprises three main structural elements: a 190-helix
(residues 183, 185–196), a 220-loop (residues 219–228), and a 130-
loop (residues 131–138, 140) (Fig. 2B). Additional residues (98,
144–146 and 153–159) ﬂank these structural elements and con-
tribute to the overall architecture of the RBS (Fig. 3). While HA1
domains from recent virus HAs are 81% identical to the 1968
viruses (and 70% for just the surface residues), the RBS compo-
nents are more divergent, at only 52% identity for the three
structural elements combined (Fig. 4A). An overlap of the RBS
main chains of HK68, PtChalmers73, Norway04, Malaysia05,
Perth09, Christchurch11 and Victoria11 highlights just how similar
the recent RBSs are to the earlier HAs. While the only signiﬁcant
main chain difference is a 2.5 Å movement of the 220 loop of
recent HAs away from the RBS (Fig. 2B), side chain differences
through sequence variation and/or antigenic drift (Smith et al.,
2004), have affected both the shape as well as the overall charge of
the RBS through the last 4 decades (Movie supplemental ﬁle and
Fig. 4B).
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.virol.2014.12.024
Of the 16 residues in and around the RBS that have remained
strictly conserved, 11 reside within, or point toward the sialic acid
binding pocket (Fig. 4C). Of these, Tyr98, Ser136, Trp153, His183,
Leu194, Tyr195 are critical for the proper functioning of the RBS.
Any mutations introduced at these sites either abolish or signiﬁ-
cantly reduce receptor binding (Skehel and Wiley, 2000). Fifteen
variable residues in or near the RBS were selected and frequency
diagrams were generated to assess variability with time at each
position (Fig. 5A). Results highlight that while all ﬁfteen positions
reside on structures that form the RBS (Fig. 5B), they also belong to
one of three identiﬁed antigenic sites: A, B or D (Daniels et al.,
1983; Popova et al., 2012; Stray and Pittman, 2012; Wiley et al.,
1981). From the data, residues in the 130-loop, 150-loop and 190-
helix have been under selective pressure throughout the last 46
years and residues in these regions have changed frequently
(Fig. 5A and C). For the 220-loop however, changes occurred only
during the 4 years; 1997, 2003, 2005 and 2006. Interestingly, of
the 18 years where changes were incorporated, only ten of those
years coincided with a decision by the WHO to change the H3N2
Fig. 4. (A) To assess HA RBS evolution with time, the HA sequences for A(H3N2) viruses were grouped according to year and consensus sequences of the RBS region of the
protein were generated. Data was plotted as percentage change in identity to the 1968 consensus. Datasets were also divided into separate components of the RBS,
corresponding to the 130/140-loop, the 190-helix and the 220-loop. Years where the H3 component of the Northern hemisphere vaccine was changed are marked with
brown squares and a plot of the predicted number of glycosylation sites is also shown for comparison (black dotted line). (B) Surface representation of the consensus RBS in
1968 compared to select examples from years (1979, 1992, 1997 and 2010) when the A(H3N2) component of the seasonal inﬂuenza vaccine was updated by the WHO. Each
RBS model is colored by charge. A movie highlighting change by year can be found in the supplemental online material. C) Conserved residues in and around the H3 RBS.
Throughout 46 years of circulation within the human population, sixteen residues in and around the RBS have remained conserved throughout and are represented as green
sticks.
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component of the inﬂuenza vaccine for the Northern hemisphere
(Fig. 5C). To assess whether changes at these variable sites have
affected host receptor binding and speciﬁcity, nineteen human H3
recombinant HAs (Table 1) spanning the period from 1968 to 2011
were cloned, expressed and each was subjected to glycan micro-
array analysis. Results are presented in Fig. 6 and summarized
Fig. 5. (A) Frequency diagrams of variable RBS residues. For each RBS position a frequency diagram was generated to show the frequency of amino acid changes at the site from
1968 to 2013. Lines are colored according to the chemical properties of each residue: polar (Gly, Ser, Thr, Tyr, Cys) colored green, neutral (Gln, Asn) colored purple, basic (Lys, Arg,
His) colored blue, acidic (Asp, Glu) colored red, and hydrophobic (Ala, Val, Leu, Ile, Pro, Trp, Phe, Met) colored black. Only residues that occurred at a frequency 415% in a year are
plotted on the graphs. (B) The positions for the 15 residues analyzed in Fig. 4A are highlighted as sticks on the Vict11 RBS. C) The number of residue changes on the 190-helix
(green), and 130- (blue), 150- (violet) and 220-loops (red) were totaled for each year and plotted on a stacked column graph. The years when the H3N2 component of the vaccine
were changed are marked in black.
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in Table 6 with full glycan information in the supplemental
Excel ﬁle.
Glycan binding to recHAs
From 1968, only very weak binding to avian α2-3 sialosides was
observed, highlighting the efﬁcient adaptation of the H3 RBS binding
to human receptors. Only sporadic binding signals for α2-3 sialosides
in early recHAs, PtChalmers73 (glycan ♯11, 21) and Victoria 75 (♯11),
were apparent. Beijing92 gave strong binding signals to α2-3
branched di-sialosides (♯9–12). While no avian receptor binding
was observed in Johannesburg94, all three recHAs from the late
1990s: Nanchang95, Sydney97 and Panama99 bound to a subset of
sulfated α2-3 glycans (♯6–8), albeit with diminishing signal strength
Nanchang954Sydney97cPanama99ð Þ. No binding to avian glycans
was detected by glycan array to any recHA from the year 2000
onwards.
From 1968 until 1999, the majority of the recHAs analyzed
bound well to sulfated (♯41), branched di-sialosyl (♯43–47) and
linear (♯50–59) α2-6 glycans represented on the microarrays.
Indeed, even PtChalmers73 bound well to α2-6 glycans on the
microarrays, which was surprising given the previously reported
poor binding of viruses from this era (1972–1974) (Gulati et al.,
2013). Results from the all six post-2000 recHAs revealed a greatly
reduced binding proﬁle. Wyoming03 bound to only two branched
di-sialoside glycans (♯45, 46) and ﬁve long linear α2-6 glycans
(♯56–59, 63). The later recHAs, California04, Hiroshima05, Bris-
bane07, Perth09, Victoria11, were further restricted and strong
binding signals were only observed for the longest branched (♯45)
and linear α2-6 glycans (♯58 and 59) on the array.
Glycan binding to recombinant HA protein was further ana-
lyzed by BLI using an Octet Red system (ForteBio Inc). This label
free technology was used to measure recombinant HA binding to
biotinylated glycans (30SLNLN-b and 60SLNLN-b) preloaded onto
streptavidin-coated biosensors. Results for recHA proteins high-
light the weak interactions of these glycans with many of the
proteins analyzed (Fig. 7A). While the 60SLNLN-b analog bound
preferentially to most of the proteins assayed, weaker binding to
the 30SLNLN-b was also observed for the majority of the recHAs
from the 1990s. Strongest binding signals to 60SLNLN-b were
observed for Leningrad86, Shanghai87, Nanchang95, Sydney97
and Panama99. However, while 60SLNLN binding was strong for
Wyoming03 recHA, by glycan microarray analysis (♯56), it bound
poorly, if at all, to the 60SLNLN-b glycan (Fig. 7A and B).
To probe the possible reason(s) for the loss of glycan binding
between Panama99 and Wyoming03, RBS sequence differences for
Wyoming03 HA were introduced onto the Panama99 HA framework
and the resulting proteins were analyzed for glycan binding to
microarrays (Fig. 8). To simplify the number of targets, substitutions
were combined according to the structural loops that comprise the HA
RBS (i.e. the 130-loop, 150-loop, 190-helix and the 220-loop). While
substitutions on the 130-loop (Thr128Ala and Ala131Thr) did not
appear to affect binding to human receptor analogs, when compared
to Panama99, an increase was observed in binding signals for the
avian α2-3 bi-antennary glycans (♯11, 12) on the array (Fig. 8).
Interestingly, combinations of substitutions in the 150-loop (His155Thr
and Gln156His), 190-helix (Ser186Gly and Ile194Leu) and 220-loop
(Ser220Arg, Trp222Arg and Gly225Asp) all resulted in a preference for
α2-6 glycan binding similar to that of Wyoming03, with a loss of
binding to the shorter linear sialosides (♯52–54) on the array (Fig. 8).
This suggests multiple substitutions may be responsible for the
observed enriched binding to the longer glycans represented on
the array.
Attempts were also made to structurally analyze the glycan
interactions of a recent 2011 HA, Victoria11. Diffraction data were
obtained for Victoria11 HA alone (apo) as well in human (60SLN)
and avian (30SLN) receptor analog complexes, and relevant crystal-
lographic statistics are presented in Table 2. While the avian
analog, 30SLN, was not visualized at all in the density maps, the
human analog, 60SLN, was also very poorly visualized (data not
shown), which is in agreement to recent structural data from 2005
HA (Lin et al., 2012).
Discussion
Between 1976 and 2007, it was reported that for the U.S., the
average mortality rates for those seasons during which inﬂuenza A
(H3N2) was a prominent strain, which included four post-2000 ﬂu
seasons (2001–2002, 2003–2004, 2004–2005 and 2005–2006),
were almost 3 times higher than for those seasons where other
seasonal inﬂuenza viruses were dominant (Thompson et al., 2010).
In order to maintain circulation within the human population, A
(H3N2) viruses have continually evolved, by a process called
antigenic drift, to escape from neutralizing antibodies produced
in response to infection and mass vaccination. During the past 46
years there have been 158 amino acid changes identiﬁed at 60
surface residues in the HA1 domain, of which 121 of these
changes, or 77%, are clustered within the ﬁve antigenic sites
(A–E) previously described for A(H3N2) viruses (Daniels et al.,
1983; Popova et al., 2012; Stray and Pittman, 2012; Webster and
Laver, 1980; Wiley et al., 1981). Interestingly, three of these
antigenic sites (A, B and D) also overlap signiﬁcantly (48%, 79%
and 36% of the antigenic site, respectively) with the HA RBS. Thus,
any antigenic changes in these regions might also affect receptor
binding. Indeed, while results show that the overall virus HA
structure from 2011 is essentially the same as that from 1968, the
residues comprising the RBS and antigenic sites have changed,
affecting both the surface shape and charge (Movie supplemental
ﬁle and Fig. 4B).
With respect to inﬂuenza research and surveillance, ongoing
changes within the RBS have been shown to affect established virus
assays over time. For example, until the mid-1990s, human A(H3N2)
and A(H1N1) inﬂuenza viruses agglutinated both human and chicken
red blood cells (RBCs), after which both subtypes lost the ability to
agglutinate chicken red blood cells (Grassauer et al., 1998; Medeiros
Table 1
Recombinant A(H3N2) HA proteins used in this study.
Strain GISAID
accession
number
Propagation
info in
database
Abbreviation
A/Hong Kong/1/1968 EPI240947 –a HK68
A/Port Chalmers/1/1973 EPI365202 Egg PtChalmers73
A/Victoria/3/1975 EPI131278 –a Victoria75
A/Bangkok/1/1979 EPI377537 Egg Bangkok79
A/Leningrad/360/1986 EPI385984 Egg Leningrad86
A/Shanghai/11/1987 EPI390002 Egg Shanghai87
A/Beijing/32/1992 EPI365898 Cell Beijing92
A/Johannesburg/33/
1994
EPI390018 Egg Johannesburg94
Nanchang/933/1995 EPI362794 Cell Nanchang95
A/Sydney/5/1997 EPI362863 Cell Sydney97
A/Panama/2007/1999 EPI105036 –a Panama99
Wyoming/03/2003 EPI152388 Cell Wyoming03
A/California/7/2004 EPI367105 Cell California04
A/Hiroshima/52/2005 EPI126805 Cell Hiroshima05
A/Brisbane/10/2007 EPI165489 Cell Brisbane07
A/Perth/16/2009 EPI182941 Cell Perth09
A/Christchurch/28/2011 EPI346305 Cell Christchurch11
A/Victoria/361/2011 EPI349103 Cell Victoria11
A/Texas/50/2012 EPI398417 Cell Texas12
a No information available.
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et al., 2001; Nobusawa et al., 2000). Residue 226 was highlighted as
a modulator of this effect, in that a progressive loss of HA binding to
chicken erythrocytes was observed as viruses changed from Gln226
to Leu to Ile to Val (Medeiros et al., 2001). Even the residues identiﬁed
for human adaptation of H1 subtypes, Glu190Asp and Gly225Asp
(Glaser et al., 2005; Matrosovich et al., 2000; Nobusawa et al., 2000;
Stevens et al., 2006a), were also shown to affect receptor binding to A
(H3N2) viruses. A limited study using viruses with different receptor
speciﬁcities was shown to correlate with RBC agglutination from
different species (Ito et al., 1997), and a Glu190Asp substitution, which
emerged around 1993 (Fig. 3), was identiﬁed as a possible reason for
this observed change (Nobusawa et al., 2000). This can be explained
structurally since the longer Glu190 side chain (with an additional
methylene group) can extend into the RBS and interact directly with
the 9-hydroxyl group of a bound sialic acid. In contrast, Asp190 is too
short to extend into the pocket and thus weakens the HA/receptor
interaction. From 2000 onwards, researchers reported that isolated
viruses grew poorly in both egg and cell culture systems used to
propagate viruses due to the A(H3N2) virus having reduced afﬁnity
for both human and avian receptors (Lu et al., 2006; Nobusawa et al.,
2000; Oh et al., 2008; Stevens et al., 2010). While a number of residue
substitutions in the RBS (i.e. 131, 145, 155, 156, 159, 186, 189, 192, 193,
222, 225, 226 and 227) occurred during this time that could explain
these observations, an Asp225Asn substitution that emerged during
2004–2005 was shown to affect virus binding in experiments with
α2-6-sialyllactosamine (Lin et al., 2012).
In this study, we have assessed changes in receptor binding by
glycan microarray analysis using recombinant HAs. Nineteen HAs
selected from WHO vaccine strains and spanning the period from
1968 to 2012 were cloned, expressed and their glycan preferences
were analyzed by glycan microarray (Blixt et al., 2004; Stevens et al.,
2006a). Although HA sequence selections were made to minimize
the effect of laboratory propagated strains, all of the older pre-1990
HA sequences were only available for viruses propagated from eggs
(Table 1). Only one of the ﬁve recHA sequences used from the 90s,
Johannesburg94, was listed in the database as egg propagated and it
Fig. 6. Receptor binding speciﬁcity of A(H3N2) inﬂuenza virus recHAs. Glycan microarray analysis of A(H3N2) inﬂuenza virus recHAs, as listed in Table 1. Different types of
sialoglycans on the array (x-axis) are grouped according to SA linkage: α2-3 SA (blue), α2-6 SA (red), α2-6/α2-3 mixed SA (purple), N-glycolyl SA (green), α2-8 SA (brown), β2-
6 and 9-O-acetyl SA (yellow), and asialo glycans (gray). The vertical bars denote relative ﬂuorescence intensity (RFI) and error bars in each panel reﬂect the standard error in
the signal for six independent replicates on the array. The structures of each of the numbered glycans are found in the supplemental Excel ﬁle. Speciﬁc glycan structures that
were used in biosensor assays are represented on the array as glycan 22 (α2-3) and glycan 56 (α2-6).
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did possess an obvious egg adaptation marker (i.e. Ser219Tyr) in its
sequence (Fig. S2). However, in 1994, 80% of the 124 HA sequences
deposited in the GISAID database contained a Phe or Tyr (egg
adaptation) at position 219, highlighting the difﬁculty of selecting
suitable vaccine strain sequences for these types of studies.
Glycan microarrays can assess the binding of recombinantly pro-
duced HAs to multiple well-deﬁned glycans simultaneously, and pre-
vious microarray binding analyses with inﬂuenza virions (both live and
β-propiolactone inactivated) demonstrated a good correlation with
receptor speciﬁcity, when compared to other methods of analysis
(Blixt et al., 2004; Childs et al., 2009; Rogers and D’Souza, 1989;
Rogers et al., 1985; Stevens et al., 2008, 2006a, 2006b, 2006c). Indeed,
unlike the virus studies performed previously, where no one glycan
bound to every virus tested (Gulati et al., 2013), results here highlighted
three long chain glycans (♯45, 58 and 59) that bound to all 17 recHAs
(Table 6). Results revealed that recHAs from the 1970s and 1980s bound
to the majority of α2-6 glycans represented on the arrays (Fig. 6).
RecHAs selected from the 1990s however, not only revealed reduced
binding to short linear α2-6 glycans (♯48–51) on the array, but they also
bound to a limited set of avian α2-3 glycans (♯6–12). The reason for the
binding of recHAs from the 1990s to avian receptor analogs is unclear.
While care was taken to reduce the selection of sequences of HA from
egg adapted strains, passage history of these older strains cannot be
conﬁrmed with absolute conﬁdence. RecHAs from 2000 onwards
bound to an even more restricted set of glycans, comprising only the
longest branched and linear glycans (♯45, 58 and 59) represented on the
array, which is in agreement with previous observations with H3N2
viruses (Gulati et al., 2013; Kumari et al., 2007; Walther et al., 2013).
One possible reason for a preference for binding to longer glycans
is the accumulation of potential glycosylation sites on the HA1 chain of
the viral HA. Since 1968, the number of potential glycosylation sites on
the A(H3N2) HA head has increased from 3 to 8, while the HA2
domain has remained relatively constant with just four (Fig. 2).
Positioning of glycosylation sites can have a dramatic effect on the
surface of the virus HA. For example, it can impact protein folding
(Hebert et al., 1997; Land and Braakman, 2001), conformation
(Meunier et al., 1999), and also affect distant parts of a protein through
masking or conformational changes. Although accumulating carbohy-
drates has been suggested to effect immune evasion (Kobayashi and
Suzuki, 2012; Seidel et al., 1991; Skehel et al., 1984; van Gils et al.,
2011; Vigerust et al., 2007; Wang et al., 2010; Wanzeck et al., 2011),
reducing the number of carbohydrate sites could also affect antibody
accessibility through tighter packing of antigenic epitopes on the virus
surface (Ye et al., 2000). Altering patterns of HA glycosylation has been
shown to inﬂuence receptor binding in a number of subtypes
including A(H3N2) viruses (Abe et al., 2004; Kaverin et al., 2002;
Matrosovich et al., 1999; Owen et al., 2007; Stevens et al., 2008; Yang
et al., 2013, 2012). Although this study cannot assess speciﬁc effects of
changes to glycosylation sites on HA receptor speciﬁcity, results
presented here suggest that there were no signiﬁcant differences in
binding signals between: Bangkok79 and Leningrad86 (gain of glyco-
sylation site at 246), Nanchang95 and Sydney97 (gain of glycosylation
sites: 122 and 133), Sydney97 and Panama99 (gain of glycosylation
site at 144), and between California04, Hiroshima05 and Brisbane07
(loss and gain of glycosylation site at 165). While a more restricted
binding proﬁle was observed between Panama99 and Wyoming03,
coinciding with a loss of glycosylation site at 126, the binding proﬁle of
California04 was not restored to that of Panama99, despite regaining
the same glycosylation site.
Compared to Panama99, Wyoming03 possesses 9 substitutions
around the RBS region of the molecule that may affect receptor
binding (Fig. 8). While previous research highlighted position 225 as a
key determinant of decreased receptor binding in viruses circulating
since 2005, our mutagenesis studies with Panama99 suggest more
than one sequence change may be responsible for the loss of short
chain glycan binding observed between Panama99 and Wyoming03
(Fig. 8). Adding these Wyoming03 substitutions onto the 150-loop,
190-helix and 220-loop of the Panama99 framework all resulted in a
loss of binding to the short chain glycans, suggesting that all three RBS
structural elements can affect receptor binding.
Previous studies with viruses and puriﬁed HAs have shown clear
differences in avidity between different A(H3N2) HAs to different glycan
species (Asaoka et al., 2006; Lin et al., 2012; Nycholat et al., 2012; Oh
et al., 2008). Our data complement these studies and highlight the
complex nature of inﬂuenza virus host interactions. However, while HA
receptor binding in these assays mostly correlate with one another,
there are differences in results depending on the format of the HA
under study (i.e. egg-propagated virus, cell-propagated or recombinant
protein) or how they are analyzed (i.e. cell-based, microarray or
biosensor assays). When considered together, one consistent feature
through all these studies appears to be the maintenance of binding to
the longer poly-N-acetyllactosamine sialosides. In line with previous
research using viruses (Gulati et al., 2013), our recHA data presented
here also reveals a loss of binding to shorter sialosides while the longer
ones are maintained. While Lin et al. (2012) have already highlighted a
loss of avidity in glycan binding to 2004 and 2005 viruses, our data
suggests that this loss in avidity had already started between 1999–
2003 and 150-, 220-loops as well as the 190-helix of the RBS can effect
this change to different degrees. The signiﬁcance of these results
remains unknown since the exact glycan proﬁle on the respiratory
tract epithelial cell used by inﬂuenza viruses to enter the cell and initiate
an infection is still not known. Interestingly a new glycan array, con-
taining endogenous natural glycans from the lungs of pigs, was recently
developed to characterize inﬂuenza virus receptor interactions (Byrd-
Fig. 7. (A) Detection of recHA binding to biotinylated glycans by Bio-Layer
Interferometry. RecHA binding to the biosensor tip containing either 30SLNLN-b
(light gray bars) or 60SLNLN-b glycans (dark gray bars) was assessed. The level of
recHA binding to the biosensor tip after 300 s, was measured as a wavelength shift
(measured in nanometers) and was plotted for each protein. (B) The full binding
proﬁle analysis of Panama99 and Wyoming03 binding to both single LacNAc
(30SLN-b, 60SLN-b) and Di-LacNAc (30SLNLN-b, 60SLNLN-b) sialosides.
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Leotis et al., 2014). The ‘shotgun glycomics’ approach used to isolate and
characterize these natural swine glycans could be used in the future to
develop speciﬁc human arrays containing a more natural repertoire of
glycans that are present on the host respiratory tract.
These results show that while the exact mechanism for loss of
virus binding avidity to shorter glycans with time may not be
attributed to any one speciﬁc residue change in the RBS, it is clear
that RBS changes that have occurred signiﬁcantly overlap onto the
recognized antigenic sites on the A(H3N2) virus. Thus, antigenic
drift will continue to have a major impact on receptor interactions.
Under pressure for the virus to evade the host immune system
without compromising its ﬁtness, even after 46 years, the virus
continues to be successful, maintaining its efﬁciency in infection
and transmission within the human population.
Materials and methods
Recombinant HA cloning and expression
cDNA encoding for residues 1 to 329 of the HA1 chain and 1-174 of
the HA2 chain of the mature ectodomain from each HA listed in
Table 1 was cloned into the baculovirus transfer vector, pAcGP67-B
(BD Biosciences, San Jose, CA), in-frame with an N-terminal baculo-
virus GP67 signal peptide and a C-terminal thrombin cleavage site, a
T4 ﬁbritin sequence for generating functional trimers (Frank et al.,
2001), and a His-Tag to aid puriﬁcation (Stevens et al., 2004). For HA1
domain only constructs, residues 41 to 313 of the mature HA
ectodomain from A/Perth/16/2009 (Perth09) and A/Christchurch/28/
2011 (Christchurch11) were used. Wyoming03 mutations were intro-
duced onto the Panama99 framework bymutagenesis of the wild-type
Panama99 construct, using the QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Transfection
and virus ampliﬁcation were carried out according to the baculovirus
expression system manual (BD Biosciences).
Protein expression and puriﬁcation
Secreted soluble recombinant HA (recHA) protein was recovered
from the cell culture supernatant by metal afﬁnity chromatography
and gel ﬁltration chromatography and subjected to either throm-
bin digestion as described previously (Yang et al., 2012) or trypsin
digestion (1:1000 w/w ratio of trypsin:protein). For Victoria11 HA
trimers a further treatment with EndoH was required to obtain
material suitable for crystallization (Lin et al., 2012). All HAs were
buffer-exchanged into 10 mM Tris–HCl, 50 mM NaCl, pH 8.0 and
concentrated to 13–19 mg/ml for crystallization trials.
Crystallization, ligand soaking and data collection
Initial nanoscale crystallization trials were set up using a
TopazTM Free Interface Diffusion (FID) Crystallizer system (Flui-
digm Corporation, San Francisco, CA). Conditions in which crystals
were observed were optimized at 20 1C using a modiﬁed method
Fig. 8. Effect of introducing Wyoming03 RBS residue differences onto the Panama99 recHA on glycan binding. RBS residue differences between Wyoming03 and Panama99
were grouped according to the RBS structural element they resided on and introduced collectively onto the Panama99 framework. The resulting Panama99 mutants were
expressed and analyzed by glycan microarray. Results are presented as for Fig. 5 and each graph is color coded according to the mutations introduced, as shown in the central
image of an A(H3) HA RBS. Wild-type Panama99 and Wyoming03 controls were run and analyzed in parallel.
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for microbatch under oil (Chayen, 2007). For receptor analog
complexes, crystals were soaked for 3 h in the crystallization
buffer containing 10 mM 30-Sialyl-N-acetyllactosamine (30SLN) or
60-Sialyl-N-acetyllactosamine (60SLN) (V-labs Inc., Covington, LA).
All crystals were ﬂash-cooled at 100 K, and datasets were collected
and processed with the DENZO-SACLEPACK suite (Otwinowski and
Minor, 1997). More speciﬁc information for each HA is included in
Table 2.
Structure determination and reﬁnement
All H3 HA structures were determined by molecular replace-
ment with Phaser (McCoy et al., 2007) using the HA structure from
A/Aichi/2/1968, PDB: 2HMG (Weis et al., 1990). Models were then
“mutated” to their correct sequences, rebuilt by Coot (Emsley et al.,
2010), and reﬁned with Phenix (Adams et al., 2010) and REFMAC
using TLS reﬁnement (Winn et al., 2001). The ﬁnal models were
Table 2
Data collection and reﬁnement statistics for the A(H3N2) HA crystal structures.
Hong Kong/1/
1968 (HK68)
Port Chalmers/1/
1973
(PtChalmers73)
Perth/16/2009 (Perth09) HA1
domain
Christchurch/28/2011
(Chrishchurch11)
Victoria/361/2011 (Victoria11)
Apo 30SLN 60SLN
Experimental
Protein conc.
(mg/ml)
14 13 15 19 18
Crystallization
conditions
0.1 M Tris–HCl,
pH7.9, 25% PEG
1000
0.1 M HEPES, pH7.5,
25% PEG 550 MME
0.1 MMagnesium Chloride, 0.1 M
Tris–HCl, pH8.5, 25% PEG 3350
0.2 M Calcium acetate,
0.1 M MES, pH6, 20% PEG
8000
0.1 M CAPS:NaOH, pH10.5, 30% (v/v) PEG
400
Cryoprotectant None None 20% glycerol 20% Ethylene glycerol None
Data
collection
Beamline
collected
APS, 22-BM SSRL, 9-2 APS, 22-ID APS, 22-ID APS, 22-ID
Space group I213 I213 P121 P1211 R32 R32 R32
Cell
dimensions
(Å)
155.51 Å, 155.51 Å,
155.51 Å
153.13 Å, 153.13 Å,
153.13 Å
42.47 Å, 50.57 Å, 182.26 Å 48.30 Å, 214.90 Å, 101.81 Å 100.91 Å,
100.91 Å,
383.36 Å
101.14 Å,
101.14 Å,
384.93 Å
100.73 Å,
100.73 Å,
382.61 Å
Cell angle (1) 901, 901, 901 901, 901, 901 901, 90.11, 901 901, 103.61, 901 901, 901, 1201 901, 901, 1201 901, 901, 1201
Resolution (Å) 50–2.35 (2.43–
2.35)a
50–2.1 (2.16–2.1) 50–1.9 (1.97–1.9) 50–2.5 (2.59–2.5) 50–2.1 (2.16–
2.1)
50–2.2 (2.26–
2.2)
50–2.2
(2.26–2.2)
Rsym (%) 7.3 (34.0) 7.5 (86.8) 8.4 (34.5) 8.7 (62.3) 7.5 (37.0) 7.8 (31.3) 7.1 (35.5)
I/sigma 40.0 (7.1) 27.3 (2.16) 12.8/3.6 28.1 (2.3) 36.8 (5.2) 37.1 (4.5) 43.5 (5.0)
Completeness
(%)
98.1 (99.3) 99.5 (98.0) 98.2 (100) 98.1 (95.4) 98.5 (95.1) 99.4 (96.7) 99.6 (96.6)
Redundancy 10.8 (9.8) 4.9 (4.5) 3.0 (3.0) 3.4 (3.0) 4.8 (4.6) 5.1 (4.1) 6.9 (5.5)
Reﬁnement
Resolution (Å) 30.5–2.35 (2.45–
2.35)
30–2.10 (2.16–2.10) 44.2–1.9 (1.93–1.90) 43–2.5 (2.53–2.5) 34.2–2.10
(2.15–2.10)
42.7–2.20
(2.25–2.20)
35.0–2.2
(2.26–2.20)
No. reﬂections
(total)
25,624 34,697 56,707 67,875 43,789 38,827 38,431
No. reﬂections
(test)
1,307 1,743 3,023 3,431 2,218 1,954 1,922
Rwork/Rfree 19.3/23.6 18.2/23.1 22.1/19.6 21.8/25.1 19.0/22.7 19.4/22/.6 19.0/22.3
No. of atoms 4,484 4,384 4,954 8,827 4,280 4,195 4,187
r.m.s.d.—Bond
length (Å)
0.005 0.007 0.002 0.009 0.005 0.004 0.006
r.m.s.d.—Bond
angle (1)
0.923 1.041 1.168 1.264 0.931 0.838 1.021
MolProbityb
scores
Favored (%) 95.7 94.5 97.8 95.2 96.3 95.3 95.1
Outliers (%) 0.2 0.6 0 0.2 0 0.4 0.6
PDB code 4WE4 4WE5 4WE6 4WE7 4WE8 4WE9 4WEA
a Numbers in parentheses refer to the highest resolution shell.
b Davis et al. (2007).
Table 3
Sequence identity (%) of recHAs used in structural analyses. Only the sequence of the HA fragments used in the expression constructs for the full-length ectodomain (FL) or
HA1 domain (HA1) were used in the calculations.
HK68 PtChalmers73 Perth09 Christchurch11 Victoria11
FL HA1 FL HA1 FL HA1 FL HA1 FL HA1
HK68 100 100 97 96 87 79 86 78 86 78
PtChalmers73 97 96 100 100 88 81 88 80 87 80
Perth09 87 79 88 81 100 100 98 96 98 97
Christchurch11 86 78 98 80 98 96 100 100 98 96
Victoria11 86 78 87 80 98 97 98 96 100 100
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assessed using MolProbity (Davis et al., 2007). Statistics on data
processing and reﬁnement are presented in Table 2.
Glycan binding analyses
Glycan microarray printing and recombinant HA analyses have
been described previously (Blixt et al., 2004; Stevens et al., 2008,
2006a, 2006c) (see Supplemental Excel ﬁle of glycans used in
these studies). For biosensor studies, biotinylated glycans: Neu5Ac
(α2-3)Gal(β1-4)GlcNAcβ-Biotin (30SLN-b), Neu5Ac(α2-3)Gal(β1-4)
GlcNAc(β1-3)Gal(β1-4)GlcNAcβ-Biotin (30SLNLN-b), Neu5Ac(α2-6)
Gal(β1-4)GlcNAcβ-Biotin (60SLN-b) and Neu5Ac(α2-6)Gal(β1-4)
GlcNAc(β1-3)Gal(β1-4)GlcNAcβ-Biotin (60SLNLN-b), obtained from
the Consortium for Functional Glycomics (www.functionalglyco-
mics.org) through the resource request program, were coupled to
streptavidin coated biosensors (Fortebio Inc.). Recombinant HA
was diluted to 4.42 mM trimer in kinetics buffer (PBS containing
0.02% Tween 20, 0.005% sodium azide and 100 mg/ml bovine
serum albumin). Bio-Layer Interferometry (BLI) analyzed binding
on an Octet Red instrument (Fortebio Inc., Menlo Park, CA)
according to the manufacturer’s instructions and data were
analyzed using the system software.
PDB accession codes
The atomic coordinates and structure factors of each HA model
described herein are available from the RCSB PDB database (www.
pdb.org) under the accession codes listed in Table 2.
Table 4
Comparison of RMSD (Å) for HA monomers. For analyses, the Cα atoms of residues,
HA1: 8–319, HA2: 21–165 for HK68 were superimposed by sequence and structural
alignment onto the equivalent regions of the other HAs.
PtChalmers73 Norway04 Malaysia05 Victoria11
HK68 0.39 0.76 0.73 0.68
PtChalmers73 0.78 0.76 0.74
Norway04 0.13 0.52
Malaysia05 0.45
Table 5
Comparison of RMSD (Å) for HA1 domains. For analyses, the Cα atoms of residues, HA1: 8-319 for HK68 were superimposed by sequence and structural alignment onto the
equivalent regions of the other HAs.
PtChalmers73 Norway04 Malaysia05 Perth09 Christchurch11 Victoria11
HK68 0.27 0.66 0.65 0.8 0.7 0.58
PtChalmers73 0.69 0.68 0.78 0.71 0.61
Norway04 1.03 0.56 0.38
Malaysia05 1.01 0.55 0.37
Perth09 0.81 0.61
Christchurch11 0.64
Table 6
Comparison of the detailed sialoside receptor speciﬁcity of H3 inﬂuenza virus recHAs.
Glycans Grapha 1968 1973 1975 1979 1986 1987 1992 1994 1995 1997 1999 2003 2004 2005 2007 2009 2011
α2-3
Sulfatedb 4–8 . . . . . . . . þþþ þþþ . . . . . . .
Branched di-sialyl 9–12 . þ þ . . . þþþ . . . þ . . . . . .
Linear 13–26 . . . . . . . . . . . . . . . . .
Fucosylated 27–34 . . . . . . . . . . . . . . . . .
Internal 35–40 . . . . . . . . . . . . . . . . .
α2-6
Sulfated 41 þþþ þþþ þþþ þþþ þþþ þþþ þþþ . þþþ þþþ þþþ . . . . . .
Branched mono-sialyl 42 . þþ . þ þþþ þþþ . . . þ . . . . . . .
Branched di-sialyl 43–47 þþ þþþ þþ þþþ þþþ þþþ þþþ þþ þþþ þþþ þþþ þþ þþ þ þ þ þ
Linear (length)c
2 48–49 . . . þþ þþþ þþþ . . . . . . . . . . .
3 52–54 þ þþþ . þþþ þþþ þþþ þ . þþ þþ þþþ . . . . . .
4 55 þþþ þþþ . þ þþþ þþ þþ . þþ . . . . . . . .
5 56 þ þþþ þþ þþþ þþþ þþþ þþþ þþþ þþ þþþ þþþ þþþ þ . . . þ
6 57 . þþ . þþ þþþ þþþ þ þ þ þþþ þþþ þþþ . . . . þþ
7 58–59 þþ þþþ þþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ þþþ
Internal 60–61 . þ . . þ . þ . . . . . . . . . .
Other
Sialic acid 1–3 . þ . þþþ þþþ þþþ þ . . . . . . . . . .
Mixed α2-3/α2-6 64–67 þ þþþ þ þþþ þþþ þþþ þþþ . þ þþ þþþ . . . . . .
non-α2-3 or α2-6 68–88 . . . . . . . . . . . . . . . . .
asialo 89–96 . . . . . . . . . . . . . . . . .
No binding
a Members of each group are identiﬁed according to the graph number used in the microarray data in Fig. 5 and correspond to numbers in the complete glycan list
(supplemental Excel ﬁle).
b Binding of samples to glycan subclasses are qualitatively estimated based on relative strength of the signal for the data shown in Fig. 5: strong 410,000 (þþþ),
medium 45000 (þþ), weak 41250 (þ), no binding o1249 (.).
c Length refers to the number of monosaccharides in the glycan chain, including SA.
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